425: Waters Corp. Details Integration with BD SpinCo

Waters Corporation provides an update on the integration planning for its proposed business combination with Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses.

Summary

• Waters Corporation is progressing with the integration of Becton, Dickinson and Company's (BD) Biosciences (BDB) and Diagnostic Solutions (DS) businesses, referred to as SpinCo.
• The transaction is expected to be completed around the end of the first quarter of calendar year 2026.
• An Integration & Transformation office (IO) has been established to guide the transformational integration.
• Waters President & CEO, Udit Batra, emphasizes competence, courage, and compassion as key qualities for successful organizational change and transformation.
• Over 120 team members from BDB, DS, and Waters participated in a Summit on Integration Planning and Transformation to align on the path ahead and ensure seamless Day 1 continuity.
• Facilities that solely support the manufacturing of products for BDB and/or DS will transfer to Waters, including sites in Cayey, Puerto Rico; Cockeysville, Maryland; Drachten, Netherlands; Grayson, Georgia; Heidelberg, Germany; Hunt Valley, Maryland; Mebane, North Carolina; Milpitas, California; Quebec, Canada; Salamanca, Spain; San Diego, California; Sparks, Maryland; and Suzhou, China.
• Customer communication will remain unchanged until the transaction closes, with proactive updates planned at close to ensure a seamless transition.

Sentiment

Score: 7

Explanation: The filing conveys a positive and proactive tone regarding the integration process, emphasizing strategic planning, cultural alignment, and a clear path forward. While it lists standard risks associated with M&A, the overall sentiment is one of confidence in the successful completion and value creation of the business combination.

Positives

• Active and structured integration planning is underway with a dedicated Integration & Transformation office (IO).
• Leadership emphasizes a thoughtful approach to cultural integration, aiming to create a new, stronger combined culture.
• A summit involving over 120 team members from all involved entities demonstrates strong collaboration and alignment on integration goals.
• Clear communication strategy for employees and customers is being implemented, aiming for seamless transition post-close.

Risks

• One or more closing conditions, including regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval for the transaction, or impose conditions, limitations, or restrictions.
• The required approval by Waters stockholders may not be obtained.
• The proposed transaction may not be completed on the terms or in the timeframe expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company.
• Failure to realize the anticipated benefits of the proposed transaction, including synergies, due to delays in completion or integration.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect the timing or occurrence of the transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Potential impacts of the U.S. government shutdown that began in October 2025.
• Actions by third parties, including government agencies.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Risk of greater than expected difficulty in separating SpinCo's business from BD's other businesses.
• Disruption of management time from ongoing business operations due to the pendency of the transaction.
• Other effects of the pendency of the transaction on relationships with employees, customers, suppliers, or other counterparties.

Future Outlook

The proposed business combination between Waters and BD's Biosciences and Diagnostic Solutions businesses is expected to close around the end of the first quarter of calendar year 2026. The Integration & Transformation office is focused on ensuring a successful integration, aiming to unlock the full value of the combination and create a new, stronger company culture. Management anticipates a seamless transition for customers post-close.

Management Comments

• "Culture is not something that you impose. Culture is lived by repetition. And that becomes part of the DNA of the company." Udit Batra, Waters President & CEO
• Udit Batra reflected on transformation as a journey, not an event, highlighting competence, courage, and compassion as qualities for effective organizational change.

Industry Context

NA

Legal Proceedings

• Stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• **Shareholders:** The combination aims to unlock full value, but risks include failure to realize anticipated benefits and potential litigation.
• **Employees:** Integration involves cultural transformation, potential changes in roles and responsibilities, and a focus on retaining key personnel. Management emphasizes compassion and understanding during change.
• **Customers:** The goal is a seamless transition with no changes to current operations until the transaction closes, followed by proactive communication of any changes.
• **Suppliers/Counterparties:** Relationships may be affected by the pendency of the proposed transaction.

Next Steps

• Continue operating as separate companies until the transaction is completed.
• File relevant materials with the U.S. Securities and Exchange Commission (SEC), including a registration statement on Form S-4 by Waters and a registration statement on Form 10 by SpinCo.
• Obtain required regulatory approvals and Waters stockholder approval.
• Communicate any changes to customers proactively at the close of the transaction.
• Share more updates in future integration newsletters.

Key Dates

Recommendation

This filing is an operational update on an already announced business combination, providing details on integration planning rather than new financial performance or material strategic shifts. It reiterates the expected timeline and outlines the structured approach to integration. While the tone is positive regarding the integration process, it does not present new information that would significantly alter the investment thesis for Waters Corporation at this stage. Investors should 'hold' as they await the completion of the transaction and subsequent financial reporting of the combined entity, while being mindful of the outlined risks.

Keywords

Waters Corporation, Becton Dickinson, BD Biosciences, Diagnostic Solutions, SpinCo, Merger, Acquisition, Integration, SEC Filing, Corporate Governance, Life Sciences, Diagnostics